GSK plc (GSK) P/E Ratio History
Historical price-to-earnings valuation from 2000 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 2, 2026, GSK plc (GSK) trades at a price-to-earnings ratio of 16.2x, with a stock price of $59.13 and trailing twelve-month earnings per share of $2.79.
The current P/E is 14% below its 5-year average of 18.8x. Over the past five years, GSK's P/E has ranged from a low of 12.2x to a high of 34.0x, placing the current valuation at the 35th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, GSK trades at a 32% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, GSK trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GSK DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Vaccines and plasma-derived therapies peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
MRKMerck & Co., Inc. | $307B | 17.0 | 0.80Best | +8% |
PFEPfizer Inc. | $157B | 20.3 | - | -4% |
GSKGSK plc | $119B | 16.2Lowest | - | +119% |
SNYSanofi | $118B | 20.3 | - | -7% |
GRFSGrifols, S.A. | $2B | 33.5 | - | +156%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $49.04 | $2.76 | 17.8x | -63% |
| FY2025 Q3 | $43.70 | $2.66 | 16.4x | -66% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $38.40 | $1.65 | 23.2x | -52% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $38.74 | $1.51 | 25.6x | -47% |
| FY2024 Q4 | $33.82 | $1.23 | 27.5x | -43% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $40.88 | $1.20 | 34.0x | -29% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $38.50 | $1.95 | 19.7x | -59% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $42.87 | $2.19 | 19.6x | -59% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $37.06 | $2.41 | 15.4x | -68% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $36.25 | $2.98 | 12.2x | -75% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $35.64 | $2.64 | 13.5x | -72% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $35.58 | $2.26 | 15.7x | -67% |
Average P/E for displayed period: 48.1x
See GSK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GSK Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare GSK vs AGIO
See how GSK stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is GSK stock overvalued or undervalued?
GSK trades at 16.2x P/E, near its 5-year average of 18.8x. The 35th percentile ranking places valuation within normal historical bounds.
How does GSK's valuation compare to peers?
GSK plc P/E of 16.2x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is GSK's PEG ratio?
GSK PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2000-2025.